Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chech it.
Since the global in vitro diagnostics (IVD) cancer market is expected to maintain robust growth over the next five years, there are increasing rumors and speculation that Radient may be positioned to be acquired or partnered with a large pharmaceutical or diagnostics company. Some industry observers note that many of the recent actions and announcements by the company reflect a corporation pursuing potential opportunities on a bigger stage.
“They’ve announced that they’re divesting and spinning-off all of their non-cancer detection related assets,” said one banker who approached the company with a capital offer in recent days. “All of their debt holders also decided and were granted equity positions instead. That’s unusual, unless you know something is about to change in the way the business has been operating.”
That CEO Douglas McClellan cut plans for a ski-vacation with his family short in order to secretly join select members of his board of directors at a series of previously unscheduled meetings in San Francisco; where industry leaders have gathered, may not help silence some of the speculation.
Unlike many of its peers, the company had not previously scheduled presentations at any of the three biotech conferences taking place there this week.
When asked about the developments, one company official pointed to a recently issued a press release in which RPC states its policy is not to comment on unusual market activity or rumors.
One source familiar with the company says that the Radient team has declined other offers for capital recently, including a significant deal that was presented to them by Rodman & Renshaw on Tuesday afternoon.
Instead of announcing the study data which some were expecting on Tuesday morning, the company issued a press release contrasting Radient’s FDA-cleared Onko-Sure(R) IVD cancer test against the recently announced, but yet to be named test that Johnson and Johnson (NYSE:JNJ) and Massachusetts General Hospital will develop over the next few years for a reported $30 million investment.
By their own account, the company appears focused and committed to pushing its test kits and convincing oncologists to adopt the Onko-Sure(R) detection platform as a new standard. In early November, the company announced that they had been invited and would be participating in nearly every major cancer medicine conference throughout the world during 2011.
What's happen guys....I have been in for two weeks and I am holdin but whats your guys exsit plans?
Form 8-K for YRC WORLDWIDE INC.
--------------------------------------------------------------------------------
2-Aug-2010
Other Events
Item 8.01. Other Events.
As previously disclosed, YRC Worldwide Inc. (the "Company") entered into an agreement with certain investors to issue and sell up to $70 million in aggregate principal amount of its 6% Convertible Senior Notes due 2014 (the "Notes") in a private placement. The Notes are subject to semi-annual interest (the "Interest") and, pursuant to certain terms contained in the Notes, the Company intends to pay the Interest due on August 15, 2010 (the "Interest Payment Date") in shares of its common stock. The amount of Interest payable on the Interest Payment Date will be $28.67 per $1,000 in principal amount of the Notes.
The number of shares of common stock ("Shares") that will be issued in respect of the Interest will be calculated as set forth in the Notes. The Shares will be issued in reliance on certain exemptions from the registration requirements of the Securities Act of 1993, as amended, and the rules and regulations promulgated thereunder. This Current Report on Form 8-K is neither an offer to sell nor a solicitation of an offer to buy the Shares or any other securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful.
We are gonna have to wait until 10-Q and an update from the company on the CVR. Just keep buying if you can.
300 share signal...I need shares??? still loading...
It's just a matter of time..They can't keep it down for ever.
Oxaliplatin...If we get news on the extended sales next....IT'S ON!!!!
APP Pharmaceuticals may market liquid and lyophilized Oxaliplatin products through at least June 30, 2010 and resume marketing the products on August 9, 2012.
According to IMS data, U.S. sales of Eloxatin® in 2009 were $993 million1. According to 2009 IMS data, combined U.S. sales of Eloxatin® and generic oxaliplatin were approximately $1.35 billion1.
APCVZ Huge Approval..you guys might might want to take a look.
Press Release Source: APP Pharmaceuticals, Inc. On Tuesday June 29, 2010, 1:01 am
SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ - News) announced today that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited (NSE:FKONCO) (BSE:532545 - News). APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. Anastrozole is therapeutically equivalent to the reference-listed drug Arimidex®, which is currently marketed by the innovator AstraZeneca.
APP will market Anastrozole in 1 mg tablets. According to IMS data, 2009 sales of the branded product in the United States were approximately $916.8 million, with approximately 105 million tablets sold annually.
“The approval of Anastrozole further expands APP's product portfolio in the strategically important Oncology segment,” said John Ducker, president and chief executive officer of APP Pharmaceuticals. “We are delighted to be able to offer this important oral medication to new customers in the retail pharmacy channel.”
Huge News...more to come!!!!!
PEMETREXED: Clould get approved this week!!!
http://www.accessdata.fda.gov/scripts/cd...
Another down day???...That seems to be the trend when we have good news. I think it's a matter of time before we move up. Dont give in to them and sell your shares because you get frustrated, thats what they want. JM
APCVZ..another FDA appoval today
NO way (split)!!!...wait until July for 2nd Q should be huge!!!.....The gap is being filled here, nice and steady clime better then huge gap and no fill!!!
Tip of the ICEBURG....with news of extended sales of Oxaliplatin past June will be huge!!!!!
Yes...I think so...do your DD....more news to come this week!!!
Premarket Volume looks great...
I think we get more news this week...
APCVZ up 17% pre market!!!!
Thanks you, but what about as a company?
Hey DOC, what do you find most atractive about this stock?
Thanks did some DD this morning looks good.
Could you please provied a link? I'm thinking of jumpimg in.
Everybody wants a piece of this action!!! WORD IS OUT.
CKECK THIS OUT....
.No web site (promised ohhh it will be up next week, ya right
.No proceeds from sale of Mockingbird(promised)
.Stock buy back(promised twice now)
.Buy out never happened
Bro I can can go on and on save your money.
Dude I have been following this stock for a very long time and all they do is lie my friend. HGLC makes promises they never keep. How long have you been waiting for that wed site?
I can can go on and on about the lies. please go back and read some of these PR's, I;m not bashing I just hate to see HGLC do this to people it wrong.
SIRI up .189 in premarket it looks like its in good shape!
niter talk 2 me whatcha see?
Bud just a word of advice do your own homework don’t take what someone says on a board as reason to invest. This company has patents pending that are very important in the stem cell industry and the also have several subsidiaries, so don’t think that just
because they are involved in a venture to recycle airplane parts that this company is one dimensional. Do your homework
Nice we have to wait until Nite is finished..... Usally with the big speads means MM tring to snag everything in between.
I was looking at their past PR's and they don't put em out very often. I hope we don't have to wait to long to update the shareholder.
Yup yup, when the mm's let it go be ready.
Thanks Niter, looks good.
.02's up again
I'm telling you
WHY? Proof.
18's gettin blasted.
Let her Go!!!!
Ya some news and a little volume would be nice.